At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 17 enrolled
Drug / intervention
ACZ885biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Extension Study to Assess Efficacy, Safety and Tolerability of Canakinumab and the Efficacy and Safety of Childhood Vaccinations in Patients With Cryopyrin Associated Periodic Syndromes (CAPS)
In Brief
A Phase 3 clinical trial evaluating ACZ885 for Cryopyrin-associated Periodic Syndromes and 3 related conditions. Completed, enrolled 17 participants across 12 sites in 7 countries.
Detailed Summary
This trial will provide long-term safety, efficacy and tolerability of ACZ885 in CAPS patients that completed the CACZ885D2307 study
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
CountriesBelgium, Canada, France, Germany, Spain, Switzerland, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
First PostedApr 2012
Primary CompletionOct 2015
TodayJul 2026
First PostedApr 12, 2012
Enrollment StartJan 16, 2012
Primary CompletionOct 13, 2015
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 14.2 years ago
Interventions
ACZ885biological